Columbia Wanger Asset Management’s Standard BioTools LAB Stock Holding History

Columbia Wanger Asset Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,777,282	Closed	-$16M	–	202
2016 Q2	$16M	Sell	1,777,282 -278,722	-14%	-$2.62M	0.19%	157
2016 Q1	$16.6M	Buy	2,056,004 +267,231	+15%	+$1.93M	0.18%	149
2015 Q4	$19.3M	Buy	+1,788,773	New	+$17.6M	0.19%	150

Other funds holding LAB

Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Emerald Acquisition Seattle, Washington $51.8B AUM

Neuberger Berman Group New York $150B AUM 40.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Columbia Wanger Asset Management's LAB Position: Q3 2016 in Review

Columbia Wanger Asset Management sold out of Standard BioTools (LAB) in Q3 2016, closing a stake of 1,777,282 shares — an estimated $16M sold.

Columbia Wanger Asset Management first reported a position in LAB in Q4 2015 and held it in 3 quarters. The position peaked at $19.3M in Q4 2015. 98 funds tracked by Wall St. Rank hold LAB as of Q3 2016.

Columbia Wanger Asset Management reported no remaining Standard BioTools position as of Q3 2016 after selling out during the quarter.
Columbia Wanger Asset Management sold 1,777,282 Standard BioTools shares in Q3 2016, an estimated $16M.
Columbia Wanger Asset Management first reported a position in Standard BioTools in Q4 2015 and held it in 3 quarters.
Columbia Wanger Asset Management's Standard BioTools position peaked at $19.3M in Q4 2015.
98 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2016.

Based on Columbia Wanger Asset Management's 13F filing for Q3 2016, filed 10 Nov 2016.